Opeolu Adeoye

Opeolu Adeoye

Auto-generated profile, based on publicly available information

Opeolu Adeoye

Department of Emergency Medicine, Washington University in St. Louis, MO

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Stroke
Verified
Journal Article
Closed access
PDF file
OAOpeolu Adeoye
Opeolu Adeoye
RHRichard Hornung
Richard Hornung
PKPooja Khatri
Pooja Khatri
DKDawn Kleindorfer
Dawn Kleindorfer
Background and Purpose—: Recombinant tissue-type plasminogen activator (rtPA) is the only approved therapy for acute ischemic stroke (AIS). In 2004, 1.8% to 2.1% of AIS patients in the United States received rtPA. Given incentives from regulatory agencies and payors to increase rtPA use, we hypothesized that rtPA use in the United States would increase from 2005 to 2009. Methods—: AIS cases were defined by exclusion of hemorrhagic stroke and transient ischemic attack International Classification of Diseases 9 th revision codes (430, 431, 432, and 435) from diagnosis-related groups 14, 15, 524, and 559 discharges. Patients receiving thrombolytics were identified using International Classification of Diseases 9 th revision code 99.10 (Medicare Provider and Analysis Review and Premier databases) and pharmacy billing records (Premier). Change over time and differences between databases were tested using negative binomial regression. Results—: Within Medicare Provider and Analysis Review, thrombolytic use increased from 1.1% in 2005 to 3.4% in 2009 ( P <0.001 for trend). Within Premier, thrombolytic use increased from 1.4% in 2005 to 3.7% in 2009 for all cases ( P <0.001). Analysis of pharmacy billing records in Premier for 50-mg or 100-mg doses of rtPA showed that 3.4% of AIS cases were treated in 2009. Inclusion of patients with transient ischemic attack or hemorrhagic stroke International Classification of Diseases 9 th revision codes who received any thrombolytic as “ischemic stroke patients receiving rtPA” changed the rate of thrombolysis to 5.2%. Conclusions—: In 2009, 3.4% to 5.2% of AIS patients in the United States received thrombolytics, approximately double the rate of treatment in 2005. Rapid recognition and transport and quick treatment in the emergency department remain goals for further improving treatment rates.

1 October 2014 in Stroke
Verified
Journal Article
Closed access
PDF file
OAOpeolu Adeoye
Opeolu Adeoye
KAKaren C. Albright
Karen C. Albright
BCBrendan G. Carr
Brendan G. Carr
CWCatherine Wolff
Catherine Wolff
MMMicheal T. Mullen
Micheal T. Mullen
DKDawn Kleindorfer
Dawn Kleindorfer
Background and Purpose—: Only 3% to 5% of patients with acute ischemic stroke receive intravenous recombinant tissue-type plasminogen activator (r-tPA) and <1% receive endovascular therapy. We describe access of the US population to all facilities that actually provide intravenous r-tPA or endovascular therapy for acute ischemic stroke. Methods—: We used US demographic data and intravenous r-tPA and endovascular therapy rates in the 2011 US Medicare Provider and Analysis Review data set. International Classification of Diseases - Ninth Revision codes 433.xx, 434.xx and 436 identified acute ischemic stroke cases. International Classification of Diseases - Ninth Revision code 99.10 defined intravenous r-tPA treatment and International Classification of Diseases - Ninth Revision code 39.74 defined endovascular therapy. We estimated ambulance response times using arc-Geographic Information System’s network analyst and helicopter transport times using validated models. Population access to care was determined by summing the population contained within travel sheds that could reach capable hospitals within 60 and 120 minutes. Results—: Of 370 351 acute ischemic stroke primary diagnosis discharges, 14 926 (4%) received intravenous r-tPA and 1889 (0.5%) had endovascular therapy. By ground, 81% of the US population had access to intravenous-capable hospitals within 60 minutes and 56% had access to endovascular-capable hospitals. By air, 97% had access to intravenous-capable hospitals within 60 minutes and 85% had access to endovascular hospitals. Within 120 minutes, 99% of the population had access to both intravenous and endovascular hospitals. Conclusions—: More than half of the US population has geographic access to hospitals that actually deliver acute stroke care but treatment rates remain low. These data provide a national perspective on acute stroke care and should inform the planning and optimization of stroke systems in the United States.

28 September 2010 in Nature Reviews Neurology
Verified
Journal Article
Closed access
OAOpeolu Adeoye
Opeolu Adeoye
JBJoseph P. Broderick
Joseph P. Broderick

1 December 2023 in Stroke
Verified
Journal Article
Closed access
LWLawrence R. Wechsler
Lawrence R. Wechsler
OAOpeolu Adeoye
Opeolu Adeoye
FAFana Alemseged
Fana Alemseged
MBMersedeh Bahr-Hosseini
Mersedeh Bahr-Hosseini
EDEmir Deljkich
Emir Deljkich
OROn Behalf Of The Xiith Stroke Treatment Academic Industry Roundtable
On Behalf Of The Xiith Stroke Treatment Academic Industry Roundtable
The Stroke Treatment Academic Industry Roundtable XII included a workshop to discuss the most promising approaches to improve outcome from acute stroke. The workshop brought together representatives from academia, industry, and government representatives. The discussion examined approaches in 4 epochs: pre-reperfusion, reperfusion, post-reperfusion, and access to acute stroke interventions. The participants identified areas of priority for developing new and existing treatments and approaches to improve stroke outcomes. Although many advances in acute stroke therapy have been achieved, more work is necessary for reperfusion therapies to benefit the most possible patients. Prioritization of promising approaches should help guide the use of resources and investigator efforts.

13 May 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
HKHooman Kamel
Hooman Kamel
NPNeal Parikh
Neal Parikh
ACAbhinaba Chatterjee
Abhinaba Chatterjee
LKLuke K. Kim
Luke K. Kim
JSJeffrey L Saver
Jeffrey L Saver
BNBabak B. Navi
Babak B. Navi
Background and Purpose: Mechanical thrombectomy helps prevent disability in patients with acute ischemic stroke involving occlusion of a large cerebral vessel. Thrombectomy requires procedural expertise and not all hospitals have the staff to perform this intervention. Few population-wide data exist regarding access to mechanical thrombectomy. Methods: We examined access to thrombectomy for ischemic stroke using discharge data from calendar years 2016 to 2018 from all nonfederal emergency departments and acute care hospitals across 11 US states encompassing 80 million residents. Facilities were classified as hubs if they performed mechanical thrombectomy, gateways if they transferred patients who ultimately underwent mechanical thrombectomy, and gaps otherwise. We used standard descriptive statistics and unadjusted logistic regression models in our primary analyses. Results: Among 205 681 patients with ischemic stroke, 100 139 (48.7% [95% CI, 48.5%–48.9%]) initially received care at a thrombectomy hub, 72 534 (35.3% [95% CI, 35.1%–35.5%]) at a thrombectomy gateway, and 33 008 (16.0% [95% CI, 15.9%–16.2%]) at a thrombectomy gap. Patients who initially received care at thrombectomy gateways were substantially less likely to ultimately undergo thrombectomy than patients who initially received care at thrombectomy hubs (odds ratio, 0.27 [95% CI, 0.25–0.28]). Rural patients had particularly limited access: 27.7% (95% CI, 26.9%–28.6%) of such patients initially received care at hubs versus 69.5% (95% CI, 69.1%–69.9%) of urban patients. For 93.8% (95% CI, 93.6%–94.0%) of patients with stroke at gateways, their initial facility was capable of delivering intravenous thrombolysis, compared with 76.3% (95% CI, 75.8%–76.7%) of patients at gaps. Our findings were unchanged in models adjusted for demographics and comorbidities and persisted across multiple sensitivity analyses, including analyses adjusting for estimated stroke severity. Conclusions: We found that a substantial proportion of patients with ischemic stroke across the United States lacked access to thrombectomy even after accounting for interhospital transfers. US systems of stroke care require further development to optimize thrombectomy access.

1 August 2015 in Stroke
Verified
Journal Article
Closed access
PDF file
KWKyle B. Walsh
Kyle B. Walsh
PSPadmini Sekar
Padmini Sekar
CLCarl D. Langefeld
Carl D. Langefeld
CMCharles J. Moomaw
Charles J. Moomaw
MEMitchell S.V. Elkind
Mitchell S.V. Elkind
OAOpeolu Adeoye
Opeolu Adeoye
Background and Purpose—: Monocytes may contribute to secondary injury after intracerebral hemorrhage (ICH). We tested the association of absolute monocyte count with 30-day ICH case fatality in a multiethnic cohort. Methods—: Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study is a prospective, multicenter, case–control study of ICH among white, black, and Hispanic patients. In 240 adults with nontraumatic ICH within 24 hours of symptom onset, we evaluated the influence of ICH score and complete blood count components on 30-day case fatality using generalized linear models. Results—: Mean age was 62.8 years (SD, 14 years); 61.7% were men, 33.3% black, and 29.6% Hispanic. Median ICH volume was 9.9 mL (interquartile range, 4.4–26.7). After adjusting for patient age and initial hemoglobin, higher total white blood cell count ( P =0.0011), driven by higher absolute neutrophil count ( P =0.002), was associated with larger ICH volume, whereas absolute monocyte count was not ( P =0.15). After adjusting for age, Glasgow Coma Scale, ICH volume, location, and the presence or absence of intraventricular hemorrhage, baseline absolute monocyte count was independently associated with higher 30-day case-fatality (odds ratio, 5.39; 95% confidence interval, 1.87–15.49; P =0.0018), whereas absolute neutrophil count (odds ratio, 1.04; 0.46–2.32; P =0.93) and white blood cell count (odds ratio, 1.62; 0.58–4.54; P =0.36) were not. Conclusions—: These data support an independent association between higher admission absolute monocyte count and 30-day case-fatality in ICH. Inquiry into monocyte-mediated pathways of inflammation and apoptosis may elucidate the basis for the observed association and may be targets for ICH neuroprotection.